<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113615</url>
  </required_header>
  <id_info>
    <org_study_id>Bio ID 2985</org_study_id>
    <nct_id>NCT05113615</nct_id>
  </id_info>
  <brief_title>Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma</brief_title>
  <official_title>Daily Dosing of Tiotropium and Tolerance to Bronchoprotection Against Methacholine Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess if regular use of tiotropium (i.e. daily) results in loss of&#xD;
      bronchoprotection against methacholine induced bronchoconstriction in those with mild asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single dose of an inhaled muscarinic antagonist will protect against methacholine induced&#xD;
      bronchoconstriction and increase the dose of methacholine required to cause&#xD;
      bronchoconstriction about 4 doubling doses. Beta agonist bronchodilators also shift the dose&#xD;
      response curve to the right but the protection against methacholine induced&#xD;
      bronchoconstriction is lost (i.e. tolerance develops) with regular use. This study will&#xD;
      determine if bronchoprotection is lost following regular use of tiotropium.&#xD;
&#xD;
      This will be a randomized, double-blind placebo controlled study to assess the development of&#xD;
      tolerance following regular use of tiotroium in a population of mild asthmatics.&#xD;
&#xD;
      Tiotropium will be administered at the clinically recommended dose (5mcg/day) for a total of&#xD;
      8 days. Methacholine challenges will be performed at baseline (pre-treatment), at one hour&#xD;
      post first dose and on day 8, one hour after the final dose. The same will dosing schedule&#xD;
      and assessments will occur with an identical placebo inhaler.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methacholine PD20</measure>
    <time_frame>pre treatment</time_frame>
    <description>dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in the first second following a full inhalation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methacholine PD20</measure>
    <time_frame>one hour post first dose</time_frame>
    <description>dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in the first second following a full inhalation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Methacholine PD20</measure>
    <time_frame>one hours post final dose</time_frame>
    <description>dose of methacholine required to induce a 20% fall in FEV1 (volume of air forcefully exhaled in the first second following a full inhalation)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>tiotropium bromide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tiotropium bromide inhaler (Spiriva Respimat) will be used once daily (2 puffs) for a total of 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo inhaler will be used once daily (2 puffs) for a total of 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>respimat inhaler 2.5mcg/puff</description>
    <arm_group_label>tiotropium bromide</arm_group_label>
    <other_name>Spiriva Respimat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>matching placebo Respimat inhaler</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of asthma&#xD;
&#xD;
          -  asthma is currently well controlled using only occasional bronchodilators&#xD;
&#xD;
          -  baseline lung function (FEV1) is greater than 65% of the predicted value&#xD;
&#xD;
          -  exhibit bronchoconstriction to inhaled methacholine at a dose of 200mcg or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  diagnosis of another lung condition or medical condition that would pose a risk to the&#xD;
             participant if enrolled in the study&#xD;
&#xD;
          -  current smokers of nicotine products (e.g., cigarettes).&#xD;
&#xD;
          -  users of cannabis or other inhaled recreational products (e.g., e-cigarettes or other&#xD;
             vaping products) on a daily basis&#xD;
&#xD;
          -  respiratory infection within 4 weeks of entering the study&#xD;
&#xD;
          -  use of any anticholinergic agent within 30 days prior to the beginning of the study&#xD;
             (e.g., ipratropium or the study treatment tiotropium).&#xD;
&#xD;
          -  known hypersensitivity to tiotropium bromide or components of tiotropium formulation&#xD;
             (e.g., benzalkonium chloride), to atropine or its derivatives.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beth Davis, PhD</last_name>
    <phone>306-844-1444</phone>
    <email>beth.davis@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>tiotropium, bronchoprotection, tolerance, methacholine PD20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

